Roux-en-Y Gastric Bypass

Area of Science:

• Bariatric surgery
• Metabolic disorders
• Psychiatric comorbidity

Background:

• Roux-en-Y gastric bypass (RYGB) is a leading bariatric surgery for obesity.
• RYGB demonstrates long-term efficacy for metabolic disorders.
• The study investigates RYGB's impact on metabolic syndrome and psychiatric conditions.

Purpose of the Study:

• To evaluate the effects of RYGB on metabolic syndrome (MS).
• To assess RYGB's influence on biochemical parameters linked to obesity comorbidities.
• To explore RYGB's impact on psychiatric comorbidities.

Main Methods:

• Observational retrospective cohort study.
• 146 patient records from January 2011 to January 2014.
• Metabolic and psychiatric data collected pre-surgery and at 3 and 9 months post-surgery.

Main Results:

• Significant reduction in most biochemical parameters post-RYGB.
• High-density lipoprotein cholesterol significantly increased post-RYGB.
• Over 90% remission of metabolic disorders; MS reduced to one patient at 9 months.
• No significant reduction in psychiatric comorbidity treatments.

Conclusions:

• RYGB is highly effective for treating metabolic syndrome and associated disorders.
• RYGB does not significantly improve psychiatric comorbidities.
• Further research may be needed for managing psychiatric conditions alongside RYGB.